Clinical Significance of Anti-endothelial Cell Antibody in Renal Transplant Recipients

Young Shin Shin, Chul Woo Yang, Hee Jong Ahn, Cheol Whee Park, Dong Chan Jin, Yong Soo Kim, Yoon Sik Chang and Byung Kee Bang

Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea

In order to evaluate the role of anti-endothelial cell antibody (AECA) in acute rejection in renal transplantation, serum AECA IgG titers were measured in 68 healthy controls, 111 chronic hemodialysis (HD) patients and 58 first renal transplant recipients. The AECA titer in hemodialysis patients was higher than in healthy controls (13.9 ± 5.0 vs. 4.8 ± 2.3 U/mL, p < 0.01). In transplant recipients, AECA titers were not affected by dialysis mode (HD vs. CAPD vs. non-dialysis; 9.6 ± 7.6 vs. 7.9 ± 3.9 vs. 11.9 ± 3.1 U/mL, p > 0.05). After renal transplantation, AECA titer was decreased significantly (vs. 4.7 ± 3.6 U/mL, p < 0.01). The serum AECA IgG titers increased significantly in recipients with acute rejection (6.9 ± 3.1 vs. 13.5 ± 9.9 U/mL, p < 0.01), but decreased to 5.6 ± 3.0 U/mL (p > 0.01) after formal rejection therapy. In the recipients with acute rejection (n = 27), the pre-renal transplant AECA titer was higher than in that without acute rejection (14.0 ± 8.6 vs. 7.7 ± 3.8 U/mL, p < 0.01). The results of this study lead us to conclude that pre- and post-renal transplant AECA titer might be a useful predictor for acute rejection and useful for monitoring acute rejection in renal transplant recipients.

Key Words: Antiendothelial cell antibody, Kidney transplantation, Graft rejection, acute

Introduction

Endothelial cells play a key role in the pathogenesis of vascular inflammation and immune processes. Antibodies against endothelial cells (antiendothelial cell antibody; AECA) have been reported in patients with Kawasaki syndrome, systemic lupus erythematosus, rheumatoid arthritis, hemolytic urticarial syndrome and Berger's disease. AECA can be detected in different unrelated autoimmune vasculitis and their presence generally correlates with disease activity. They also play a probable pathogenic role in vivo vessel wall damage supported by different in vitro models of direct and complement- or cell-mediated cytotoxicity. In addition, AECA can be useful in diseases lacking other specific serological markers, such as in Kawasaki syndrome or in idiopathic forms of vasculitis.

There have been several studies on molecular characterization of the endothelial cell target antigen against antibodies. In clinical transplant cases, a 90-100 kD kidney-specific antigen has been identified as the target for IgG antibodies eluted from rejecting kidneys, and IgM antibodies associated with hyperacute rejection of a kidney transplant were directed against a 97-110 kD endothelial target antigen. AECA was studied in cardiac and renal transplantation. AECA was detected in a proportion of renal transplant recipients who developed either accelerated, acute or chronic graft rejection, suggesting the role of AECA in graft rejection. In cardiac transplantation as well AECA have been associated with hyperacute rejection and humoral acute rejection.

Based on the above findings, serum AECA IgG titers were monitored before and after renal transplantation, and the association of AECA titers with acute rejection in
renal transplantation was evaluated. Our data indicate that serum AECA titer is a useful predictor for acute rejection and immunologic monitoring in renal transplant recipients.

Methods

1. Patients

In all, 68 healthy subjects, 111 hemodialysis (HD) patients and 58 first renal transplant recipients were studied. In the control group, mean age was 38 years (range 22-60) and sex ratio (MF) was 48:20. In the HD patients, mean age was 50 years (range 27-63), sex ratio (MF) was 57:54 and mean duration of HD was 57 months (range 19-96). In the renal transplant recipients, mean age was 38 years (range 26-50), sex ratio (MF) was 32:26, method of dialysis (HD/CAPD/none) was 44:10:4 and mean duration of dialysis was 29 months (range 8-50). All recipients received 12 mg/kg/day of cyclosporine A starting 2 days prior to the transplantation and the dosage was subsequently adjusted to maintain a trough cyclosporine A plasma concentration within the desired range. Intravenous methylprednisolone (125 mg) was administered intraoperatively, just prior to restoring blood flow to the allograft. Postoperatively, intravenous methylprednisolone (125 mg/day in two divided doses) was administered for 48 h. Beginning on the 3rd post-transplant day, 60 mg prednisolone per day was administered until day 7, at which time the steroid dosage was tapered to 15-20 mg/week for 1 month. Acute rejection was observed in 27 of the 58 renal allograft recipients and diagnosed by graft biopsy findings based on the Banff schema (15). Of the 27 graft biopsies, 10 were very mild AR, 4 were grade I AR, 3 were grade II AR, 3 were normal, 3 were others and 4 were inadequate specimens. Rejection episodes were treated with a 6-day course of intravenous methylprednisolone (250 mg every 12 h for 3 days, and then 125 mg every 12 h for 3 days), followed by gradual tapering to maintenance doses.

2. Serum Sample Collection

Serum samples of renal transplant recipients were serially obtained before and after renal transplantation with 3-5 day interval for 1 or 2 months after transplantation. Serum samples were collected and stored at -20°C until used.

3. Endothelial cell culture

Endothelial cells were harvested from human umbilical cord veins by collagenase using established methods (16). Endothelial cells were grown onto 0.1% gelatin coated tissue culture flasks (Costar, Cambridge, MA, USA), in medium M-199 (Gibco BRL, Gaithersburg, MD, USA) supplemented with 20% heat-inactivated newborn calf serum, 200 U/mL penicillin, 200 g/mL streptomycin, 2 mM L-glutamine, 25 g/mL endothelial cell growth factor (Boehringer Mannheim, Germany) and 5 U/mL heparin. Cells were fed every three days and, when confluent, subcultured by exposure to 0.05% trypsin-0.01% EDTA (Gibco BRL, Gaithersburg, MD, USA). The cells were used between passage 2 to 5.

4. Anti-endothelial cell antibody assay

The ACEA were detected using the method of Calos et al (9) with an ELISA. Cultured endothelial cells placed onto gelatin coated 96-well microtiter plates (Costar, Cambridge, MA, USA) at a concentration of 2 x 10^4 cells/well in complete medium. Cells reached a confluent monolayer in about 48 h. Plates were washed twice with Hank's Balanced Salt Solution (HBSS, Flow Labs., Irvine, Scotland, UK). After two times, washes with HBSS, 100 ug of the test serum (diluted 1:100 with HBSS), were added to each well triplicate. The plates were incubated for 2 h at room temperature and then washed with HBSS three times. One hundred microliters of peroxidase conjugated rabbit anti-human IgG (diluted 1:1000 with HBSS) were added to each well and incubated for 1 h at room temperature. Four time washes were then performed with HBSS. One hundred microliters of o-phenylenediamine dihydrochloride were added to each well and incubated for 15 min at room temperature. And then 100 μl of 3M NaOH were added to each well. The plates were read at 405 nm in an ELISA reader.

The amount (U/mL) bound of anti-human IgG of the positive control sera at the standard dilution of 1/50 was arbitrarily chosen as 100 U/mL endothelial cell activity. Positive control sera were run on each plate and test sample binding activity was expressed as a percentage of the positive reference sera. Values greater than three standard deviations above the mean value of 48 normal subjects were considered increased.

5. Statistical analysis

Mean values are reported ± SD. Nonparametric tests were used for the statistical analyses. The Wilcoxon rank sum test was used for an unpaired comparison between
the two groups, and the Wilcoxon Sign Rank Test for comparison within the group. $P < 0.05$ was considered significant.

**Results**

1. *Anti-endothelial cell antibody titers in normal controls and dialysis patients*

The AECA tier in patients with HD was higher than that in healthy controls (13.9±5.0 vs. 4.8±2.3 U/ml, *p*<0.01) (figure 1). In transplant recipients, AECA titers were 9.6±7.6, 7.9±3.9 and 11.9±3.1 U/ml in recipients with HD, CAPD, and non-dialysis, respectively. This suggests that AECA tiers were not affected by the dialysis modes (figure 2).

![Figure 1](image1.png)

**Figure 1.** AECA tiers in sera of healthy controls and hemodialysis (HD) patients.

![Figure 2](image2.png)

**Figure 2.** AECA tiers in sera of recipients before kidney transplantation (KT) according to dialysis modality

2. *The AECA tiers after kidney transplantation and recipients with acute rejection*

The AECA tiers at 1 week after the transplantation were significantly decreased as compared with pre-transplant tiers (4.7±3.6 U/ml vs. 10.6±7.1, *p*<0.05) (figure 3). In recipients without acute rejection episode, significant changes of AECA tiers were not reported for following 2 months. Thus AECA tiers at 2 months after the transplantation were similar to those at 1 week (5.0±2.1 vs. 4.7 ± 3.6 U/ml) (figure 3).

In acute rejection episodes (*n*=27), AECA tiers increased significantly compared to pre-rejection tier (6.9±3.1 to 13.5±9.9 U/ml, *p*<0.01) (figure 4), but decreased with successful anti-rejection treatment (13.5±9.9 U/ml vs.

![Figure 3](image3.png)

**Figure 3.** Serial changes of AECA tiers in patients without acute rejection episodes

![Figure 4](image4.png)

**Figure 4.** Serial changes of AECA tiers in patients who showed acute rejection episodes

![Figure 5](image5.png)

**Figure 5.** The relationship between the pre-transplant AECA tiers and acute rejection (AR)
Clinical Significance of Anti-endothelial Cell Antibody in Renal Transplant Recipients

5.6±3.0 U/mL, p<0.01) (figure 4). In the recipients who experienced acute rejection (n=27), the pre-transplant AECA titer was higher than that without acute rejection (n=31) (14.0±8.6 vs. 7.7±3.8 U/mL, p<0.01) (figure 5).

Discussion

Our study demonstrates an association of AECA titer with acute rejection in renal transplant recipients. The AECA IgG titers significantly increased in recipients with acute rejection, and decreased with successful anti-rejection treatment. The pre-transplant IgG AECA titers in recipients with acute rejection were higher than in those without acute rejection episode. This finding suggests that AECA itself might be responsible for acute rejection processes and elevated AECA titer in pre-transplant recipients may be a predictor of acute rejection.

Vascular endothelial cells are strategically positioned within a transplanted organ and are considered possible targets in most forms of rejection. Recently, AECA was described in sera from patients affected by autoimmune diseases, and it plays a probable pathogenetic role in vivo vessel wall damage supported by different in vitro models of direct and complement-or cell-mediated cytotoxicity. It is generally accepted that AECA activity does not involve HLA class I and II or ABO blood group antigens. In transplantation, AECAs directed against non-HLA molecules on graft endothelium have been detected in a proportion of allograft recipients who developed accelerated, acute or chronic graft rejections, suggesting that antibodies reactive with the endothelium may take part in graft rejection. Karuppan et al. demonstrated that non-activated endothelial cells were not killed by the antibodies, but cytotoxic effect of AECA can be observed when activated endothelial cells bind with IL-1β. The activation of endothelial cells may occur in vivo during transplantation. After renal transplantation, endothelial cells can be activated by ischemia-reperfusion injury and inflammatory mediators (IL-1β, TNF-α, and INF-γ). The activated endothelial cells seem to be another target of acute rejection.

In this study, we found that AECA titers in end stage renal disease patients were higher than in healthy controls. The nature of the stimulus that increases production of AECA in uremic condition is not determined but two possibilities can be speculated on. First, active role of kidney in the metabolism of AECA, considering reduction of AECA IgG titer in the post-transplant period. Second, preactivated immune state in uremic condition may simulate AECA production. In contrast, decreased AECA titers after successful renal transplantation suggested the increased clearance of AECA via kidney and influence of immunosuppressive drug.

Acute rejections are considered to be due to the activation of a cell-mediated immune response and the role of humoral rejection is not well documented. Clinical categories of cellular (lymphocyte) and humoral (antibody) mechanisms of rejection are known to be interrelated. Antibody production by B cells is regulated by T cells through both cell to cell contact and secretion of regulatory lymphokines including IL-2, IL-4, and INF-γ. In this study, AECA titer were increased during acute rejection but subsequently decreased with successful anti-rejection therapy, suggesting the possibility of involvement of humoral rejection in acute rejection process. Although humoral immune responses throughout the course of the transplantation have not been measured, it would appear that both types of immune responses may occur during the course of transplantation and may contribute to the acute rejection. Increased AECA IgG titer after transplantation was associated with acute rejection. High level of pre-transplant AECA IgG titer is related with acute rejection, also. This finding suggests the role of AECA in pathogenesis of acute rejection.

The clinical importance of AECA remains to be established, but it is important to note that AECA assay frequently detects the presence of a clinically significant antibody which is not detected by the lymphocytotoxicity test and which correlates with rejection. This correlation of the AECA detection with clinical course appears to be well established.
In conclusion, monitoring for the presence of AECA may provide a valuable prognostic indicator of graft rejection and immunologic status in renal transplant patients.

REFERENCES

1. Papa ND, Gambini D, Meroni PL. Anti-endothelial cell antibodies and autoimmune diseases. Clin Rev Allergy 2:275-286, 1989
2. Leung DYM, Collins T, Lapierre LA, Geha RS, Pober JS. Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon. J Clin Invest 77:428-435, 1986
3. Van Der Zee JM, Siegert CEH, De Vreede TA, Daha MR, Heurkens AHM, Hiemstra PS, Lafeber GJ M, Daha MR, Leung DYM, Havens PL, Moake J L, Kim M, Pober JS. Immune complex deposits containing antiendothelial cell antibodies in patients with IgA nephropathy; frequency and clinical significance. Clin Immunol Immunopathol 29:450-462, 1988
4. Yap HK, Sakai RS, Bahn L, Rappaport V, Woo KT, Joyce S, Flye MW, Mohanakumar T. Characterization of anti-endothelial cell antibodies in systemic lupus erythematosus (SLE). Clin Exp Immunol 84:28-344, 1989
5. Leung DYM, Havens PL, Maule Jl, Kim M, Pober JS. Lytic anti-endothelial cell antibodies in hemolytic uremic syndrome. Lancet 2:83-86, 1988
6. Yip HK, Sakai RS, Bahn L, Rappaport V, Woo KT, Ananthuman V, Lim CH, Chiang GSC, Jordan SC. Anti-endothelial cell antibodies in patients with IgA nephropathy; frequency and clinical significance. Clin Immunol Immunopathol 29:450-462, 1988
7. Joyce S, Flye MW, Mohanakumar T. Characterization of kidney cell-specific, non major histocompatibility complex alloantigen using antibodies eluted from rejected human renal allografts. Transplantation 46:262-269, 1988
8. Karrupan SS, Tyden G, Reinhi B, Berg U, Moller E. Hyperacute rejection of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transplant Immunol 5:321-327, 1989
9. Cerilli J, Holiday JE, Fesperman DP, Folger MA. Antivascular endothelial antibod - its role in transplantation. Surgery 81:182-188, 1977
10. Clarke JL, Brasile L, Rhoades J, Thompson JS, Cerilli J. Serologic comparison anti-granulocyte and anti-VEC cytotoxicity of human myelomonocytic antigen (HMA) and vascular endothelial cell system (VEC). Transplant Proc 2:1647-1654, 1989
11. Mitemberg AMM, Meij-Paape ME, Weening JJ, Daha MR, van Es LA, van der Woude FL. Induction of antibody-dependent cellular cytotoxicity against endothelial cells by renal transplantation. Transplantation 48:681-688, 1989
12. Dunn MI, Crisp SJ, Rose M, Taylor PM, Magdi HY. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 339:1566-1570, 1992
13. Tietz D, Tuso P, Czer L, Yasunaga C, Tyan D, Fischbein M, Admon D, Banath P, Banch C, Craner DV, Mokwula L, Trento A. Characterization of antiendothelial cell and antiheart antibodies following heart transplantation. Transplant Proc 25:931-934, 1993
14. Fredrich R, Toyoda M, Lawrence SC, Czer L, Galayán K. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 67:385-389, 1999
15. Sokr K, Azelken RA, Benediktsson H, Bruck B, Jaffe EA, Nichman RL, Becker CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphological and immunologic criteria. J Clin Invest 52:2745-2756, 1973
16. Williams GM, Ter Haar A, Park LC, Nast CC, Olsen S. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 81:132-138, 1977
Clinical Significance of Anti-endothelial Cell Antibody in Renal Transplant Recipients

24. Takada M, Nadeau KC, Shaw GD, Minquette KA, Tilney NL. The cytokine-adhesion molecule cascade in ischemic/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 99:2682-2690, 1997

25. Raska K, Raskova J, Shea SM, Frankel RM, Wood RH, Lifter J, Gobrial I, Eisinger RP, Homer L. T cell subsets and cellular immunity in end-stage renal disease. Am J Med 75:734-740, 1983

26. Beaunin G, Nuet C, Mucon I, Guetteau G, Ducle T, Ouna P, Nelson DL, Bach JF, Chatenaud L. In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients. Kidney Int 32:84-88, 1987

27. Remuzzi G, Rossi EC. Effect of renal failure on granulocytes: Hematologic consequences of renal failure. In: Brenner BM, ed. Brenner and Rector's the kidney. 5th ed. p. 2178-2180, Philadelphia, W.B. Saunders, 1996

28. Perkins DL, Carpenter CB. Graft rejection: Immunobiology of transplantation. In Brenner BM, ed. Brenner and Rector's the kidney, 5th ed. p.2590-2593, Philadelphia, W.B. Saunders, 1996